Continued Significant Improvement in Skin Appearance Observed in StudySubject’s Disease Classification Improved from “Severe” to “Mild” after 6 ...

Quoin Pharmaceuticals Ltd. announced positive interim results from its clinical study of QRX003 for treating Pediatric Netherton Syndrome, showing significant improvements in skin appearance.

Gross proceeds, before deducting placement agent fees and offering expenses, are expected to be approximately $6.8 million, and includes participation from certain of the Company’s executive ...

Quoin Pharmaceuticals (QNRX) announces interim clinical data from its ongoing Investigator Pediatric Netherton Syndrome clinical study. The ...

Quoin Pharmaceuticals Ltd. announced positive interim clinical data from an ongoing study of QRX003 for Netherton Syndrome, highlighting significant improvements in skin condition and patient ...

ASHBURN, Va., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty ...

Continued Significant Improvement in Skin Appearance Observed in Study Subject’s Disease Classification Improved from “Severe” to “Mild” ...

Continued Significant Improvement in Skin Appearance Observed in Study Subject’s Disease Classification Improved from “Severe” to “Mild” after 6 Weeks Dosing Treatment area expanded from ...

Continued Significant Improvement in Skin Appearance Observed in Study Subject's Disease Classification Improved from "Severe” to "Mild” after 6 Weeks Dosing Treatment area expanded from 20% Body ...

Jan. 14, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today ...